Beacon Biosignals applies AI-driven neurotechnology to accelerate neuroscience innovation and bring life-changing treatments to patients faster. The company combines clinical and research expertise in neuroscience, machine learning, and product development to develop quantitative EEG-based biomarkers for neurological, psychiatric, and sleep disorders. Beacon’s mission is to unlock brain data to improve diagnosis, stratify patient populations, and shorten the path from symptom to solution.

Beacon offers an end-to-end platform that integrates a clinical-grade, FDA-cleared at-home sleep EEG headband with secure cloud analytics. AI models trained on 200,000+ hours of EEG data extract pharmacodynamic and disease biomarkers, enabling low-latency event monitoring, objective sleep endpoints, and deeper insights into treatment effects. Clinical Study Operations and Scientific Services teams support device deployment, software integration, data quality, and regulatory reporting to support trials from discovery through label expansion.

Beacon’s solutions help identify dose-dependent drug effects, characterize patient populations, and track disease progression earlier than traditional outcomes. The company is headquartered in Boston with offices in Paris and New York and a distributed global team. Leadership includes co-founders Jacob Donoghue, MD, PhD (CEO) and Jarrett Revels (CTO), and a cross-disciplinary executive team with deep experience in neuroscience, clinical operations, and machine learning.